Previous 10 | Next 10 |
Abiomed (NASDAQ: ABMD) announces the first two patients have been treated with the Impella ECP expandable percutaneous heart pump. Impella ECP is the smallest heart pump in the world. It measures 9 French (Fr) (3 millimeters) in diameter upon insertion and removal from the body. Whi...
The FDA has granted Abiomed ([[ABMD]] +1.9%) a 510(k) clearance for an all-in-one, compact cardiopulmonary bypass system, Abiomed Breethe OXY-1 System.The system provides cardiopulmonary bypass support for patients whose lungs can no longer provide sufficient end organ oxygenation. The 5...
The United States Food and Drug Administration (FDA) has granted Abiomed (NASDAQ: ABMD) a 510(k) clearance for an all-in-one, compact cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System™ . This press release features multimedia. View the full release...
Data presented at TCT Connect , the 32nd annual scientific symposium of the Cardiovascular Research Foundation, finds early identification of right heart failure and early use of Impella RP is associated with significantly higher survival rates. Early identification of patients ...
Two studies of AMI cardiogenic shock (AMICS) patients found higher survival when Impella was placed pre-PCI, compared to when Impella was placed after PCI. The findings were presented at TCT Connect , the 32nd annual scientific symposium of the Cardiovascular Research Foundation. ...
The use of Abiomed 's (NASDAQ: ABMD) Impella heart pumps reduced the rate of death, stroke, myocardial infarction, and repeat procedures in high-risk percutaneous coronary intervention (PCI) patients, according to a new study. The interim data from the healthcare company 's ...
Abiomed, Inc . (NASDAQ: ABMD) announced it will host a virtual investor meeting on Tuesday, October 20, 2020 at 8:00 a.m. EDT to review new clinical data presented at TCT Connect , the 32nd annual scientific symposium of the Cardiovascular Research Foundation. The virtual meetin...
Abiomed (NASDAQ: ABMD) announces new PROTECT III study data that demonstrates reduced rates of MACCE (composite of death, stroke, myocardial infarction and repeat procedures) when Impella is used to achieve a more complete revascularization in a single setting for high-risk perc...
The Restore EF Study demonstrates the use of contemporary best practices, including attempting a more complete revascularization with Impella -supported high-risk PCI, is associated with significant improvement of left ventricular ejection fraction (LVEF), heart failure symptoms, an...
As the coronavirus pandemic has progressed, healthcare companies engaged in the development and manufacturing of COVID-19 vaccines and therapeutics have become the darlings of the stock market. Shares of most of these companies have increased exponentially in 2020, with much of the gain...
News, Short Squeeze, Breakout and More Instantly...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support...
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 PR Newswire NEW YORK , Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent...
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have...